synchron.comHealthcare / Medical DevicesFounded: 2016Funding to Date: $118.41MM
Synchron has developed an endovascular brain computer interface that can access every corner of the brain using its natural highways, the blood vessels. Their breakthrough platform launches a new frontier for the treatment of neurological diseases: Neurointerventional Electrophysiology (Neuro EP). This company was founded in 2016 and is headquartered in Brooklyn, NY.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
12/15/2022 | Series C-1 | $872,072 | $xx.xx | $400.53MM | ARCH Venture Partners, Gates Frontier, Bezos Expeditions, Reliance Digital Health Limited, Greenoaks, Alumni Ventures, Moore Strategic Ventures, Project X, Khosla Ventures, NeuroTechnology Investors, METIS, Forepoint Capital Partners, ID8 Investments, Shanda Group, University of Melbourne | |
Price per Share
$xx.xx
Shares Outstanding
36,777
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
ARCH Venture Partners, Gates Frontier, Bezos Expeditions, Reliance Digital Health Limited, Greenoaks, Alumni Ventures, Moore Strategic Ventures, Project X, Khosla Ventures, NeuroTechnology Investors, METIS, Forepoint Capital Partners, ID8 Investments, Shanda Group, University of Melbourne
|
||||||
12/15/2022 | Series C | $74.13MM | $xx.xx | $400.53MM | ARCH Venture Partners, Gates Frontier, Bezos Expeditions, Reliance Digital Health Limited, Greenoaks, Alumni Ventures, Moore Strategic Ventures, Project X, Khosla Ventures, NeuroTechnology Investors, METIS, Forepoint Capital Partners, ID8 Investments, Shanda Group, University of Melbourne | |
Price per Share
$xx.xx
Shares Outstanding
2,657,210
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
ARCH Venture Partners, Gates Frontier, Bezos Expeditions, Reliance Digital Health Limited, Greenoaks, Alumni Ventures, Moore Strategic Ventures, Project X, Khosla Ventures, NeuroTechnology Investors, METIS, Forepoint Capital Partners, ID8 Investments, Shanda Group, University of Melbourne
|
||||||
06/03/2021 | Series B-1 | $3.87MM | $xx.xx | $139.83MM | Khosla Ventures, Forepont Capital Partners, ID8 Investments, Shanda Group, General Advance, Subversive Capital, re.Mind Capital, Arani Bose, Thomas Reardon, NeuroTechnology Inestors, METIS, University of Melbourne | |
Price per Share
$xx.xx
Shares Outstanding
360,658
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Khosla Ventures, Forepont Capital Partners, ID8 Investments, Shanda Group, General Advance, Subversive Capital, re.Mind Capital, Arani Bose, Thomas Reardon, NeuroTechnology Inestors, METIS, University of Melbourne
|
||||||
06/03/2021 | Series B | $36MM | $xx.xx | $139.83MM | Khosla Ventures, Forepont Capital Partners, ID8 Investments, Shanda Group, General Advance, Subversive Capital, re.Mind Capital, Arani Bose, Thomas Reardon, NeuroTechnology Inestors, METIS, University of Melbourne | |
Price per Share
$xx.xx
Shares Outstanding
2,849,155
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Khosla Ventures, Forepont Capital Partners, ID8 Investments, Shanda Group, General Advance, Subversive Capital, re.Mind Capital, Arani Bose, Thomas Reardon, NeuroTechnology Inestors, METIS, University of Melbourne
|
||||||
04/04/2017 | Series A | $3.54MM | $xx.xx | $14.16MM | NeuroTechnology Investors, DARPA | |
Price per Share
$xx.xx
Shares Outstanding
1,770,224
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
NeuroTechnology Investors, DARPA
|